Global Chronic Kidney Disease (CKD) Market Growth (Status and Outlook) 2023-2029

Global Chronic Kidney Disease (CKD) Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Chronic Kidney Disease (CKD) Industry Forecast” looks at past sales and reviews total world Chronic Kidney Disease (CKD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Kidney Disease (CKD) sales for 2023 through 2029. With Chronic Kidney Disease (CKD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Kidney Disease (CKD) industry.

This Insight Report provides a comprehensive analysis of the global Chronic Kidney Disease (CKD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chronic Kidney Disease (CKD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Kidney Disease (CKD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Kidney Disease (CKD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Kidney Disease (CKD).

The global Chronic Kidney Disease (CKD) market size is projected to grow from US$ 86610 million in 2022 to US$ 109860 million in 2029; it is expected to grow at a CAGR of 3.5% from 2023 to 2029.

United States market for Chronic Kidney Disease (CKD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Chronic Kidney Disease (CKD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Chronic Kidney Disease (CKD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Chronic Kidney Disease (CKD) players cover AbbVie, Allergan, Amgen, AstraZeneca, Roche, FibroGen, GlaxoSmithKline, Johnson & Johnson and Keryx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Kidney Disease (CKD) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
ACE Inhibitors
Calcium Channel Blockers
Beta Blockers
Others

Segmentation by application
Hospitals
Specialty Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Allergan
Amgen
AstraZeneca
Roche
FibroGen
GlaxoSmithKline
Johnson & Johnson
Keryx
Kissei
Pfizer
Sanofi
Teva

Please note: The report will take approximately 2 business days to prepare and deliver.